このエントリーをはてなブックマークに追加
ID 30733
JaLCDOI
フルテキストURL
著者
Noguchi, Hirofumi Okayama University
Matsumoto, Shinichi Okayama University
Matsushita, Masayuki Okayama University
Kobayashi, Naoya Okayama University
Tanaka, Koichi Okayama University
Matsui, Hideki Okayama University Kaken ID publons researchmap
Tanaka, Noriaki Okayama University
抄録
The development by the Edmonton group of a sirolimus-based, steroid-free, low-tacrolimus regimen is a significant breakthrough that allows the rate of insulin independence after islet transplantation to increase from 13% to 80% at 1 year ; however, the rate is reduced to 50% at 3 years, attributed to prolonged tacrolimus exposure. Recently, immunosuppression agents such as cyclosporine, mycophenolate mofetil, and the novel agent FTY 720 have been used instead of tacrolimus. Lymphocytedepleting antibodies such as anti-thymocyte globulin, alemtuzumab, and hOKT3gamma 1 (ala, ala) have been launched, and a costimulatory blockade of anti-CD40 monoclonal antibodies and CTLA4-Ig will be attempted in the near future. Moreover, the potential of a novel immunosuppressing peptide could now be realized using new technology called the protein transduction system. In this review, we show some of the most recent contributions to the advancement of knowledge in this field.
キーワード
islet transplantation
steroid-free
Edmonton protocol
protein transduction syst
Amo Type
Review
発行日
2006-04
出版物タイトル
Acta Medica Okayama
60巻
2号
出版者
Okayama University Medical School
開始ページ
71
終了ページ
76
ISSN
0386-300X
NCID
AA00508441
資料タイプ
学術雑誌論文
言語
English
論文のバージョン
publisher
査読
有り
PubMed ID
Web of Science KeyUT